T1	Participants 311 353	men with locally advanced prostate cancer.
T2	Participants 449 530	NCIC Clinical Trials Group PR.3/Medical Research Council PR07/Intergroup T94-0110
T3	Participants 568 615	patients with locally advanced prostate cancer.
T4	Participants 616 798	Patients with T3-4, N0/Nx, M0 prostate cancer or T1-2 disease with either prostate-specific antigen (PSA) of more than 40 μg/L or PSA of 20 to 40 μg/L plus Gleason score of 8 to 10
T5	Participants 1045 1091	RESULTS One thousand two hundred five patients
T6	Participants 1913 1957	of men with locally advanced prostate cancer
